Journal of Archives in Military Medicine

Published by: Kowsar
Crossmark

Prevalence of Kidney, Renal Pelvis, and Ureter Cancers in Isfahan Province, Iran

Zahra Tolou-Ghamari 1 , *
Author Information
1 Isfahan Kidney Transplantation Research Center, Department of Urology, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Journal of Archives in Military Medicine: June 30, 2019, 7 (1-2); e95457
  • Published Online: July 13, 2019
  • Article Type: Research Article
  • Received: June 17, 2019
  • Revised: July 1, 2019
  • Accepted: July 1, 2019
  • DOI: 10.5812/jamm.95457

To Cite: Tolou-Ghamari Z. Prevalence of Kidney, Renal Pelvis, and Ureter Cancers in Isfahan Province, Iran, J Arch Mil Med. 2019 ; 7(1-2):e95457. doi: 10.5812/jamm.95457.

Abstract
Copyright © 2019, Journal of Archives in Military Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. John J, Aldera AP, Sinha S, Lazarus J. Clear cell renal cell carcinoma with a ureteral thrombus. J Endourol Case Rep. 2018;4(1):159-62. doi: 10.1089/cren.2018.0067. [PubMed: 30426074]. [PubMed Central: PMC6225074].
  • 2. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9(1-6):461-73. doi: 10.3233/CBM-2011-0176. [PubMed: 22112490]. [PubMed Central: PMC3308682].
  • 3. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol. 2008:782381. doi: 10.1155/2008/782381. [PubMed: 19009036]. [PubMed Central: PMC2581742].
  • 4. Algaba F, Moreno A, Trias I. Tumores renales. Uropatologia tumoral. Barcelona, Spain: Pulso Ediciones; 1996. p. 21-101. Spanish.
  • 5. Robles JE, Rosell D, Zudaire JJ, Berian JM. [Epidemiology of renal parenchymal tumors]. J Med Univ Navarra. 1999;43(2):68-76. Spanish.
  • 6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30. [PubMed: 16514137].
  • 7. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352(9141):1691-6. doi: 10.1016/S0140-6736(98)01041-1. [PubMed: 9853456].
  • 8. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-57. doi: 10.1038/nrurol.2010.46. [PubMed: 20448658]. [PubMed Central: PMC3012455].
  • 9. Stang A, Buchel C. A novel approach for estimating the nationwide incidence of renal cancer. Emerg Themes Epidemiol. 2014;11:8. doi: 10.1186/1742-7622-11-8. [PubMed: 25057278]. [PubMed Central: PMC4108273].
  • 10. van de Schans SA, Aben KK, Mulders PF, Haanen JB, van Herpen C, Verhoeven RH, et al. Modest improvement in 20 years of kidney cancer care in the Netherlands. Eur J Cancer. 2012;48(12):1822-30. doi: 10.1016/j.ejca.2012.01.033. [PubMed: 22365640].
  • 11. Cleries R, Esteban L, Borras J, Marcos-Gragera R, Freitas A, Carulla M, et al. Time trends of cancer incidence and mortality in Catalonia during 1993-2007. Clin Transl Oncol. 2014;16(1):18-28. doi: 10.1007/s12094-013-1060-y. [PubMed: 23740137].
  • 12. Souza DL, Bernal MM. [Incidence, prevalence and mortality of kidney cancer in Spain: Estimates and projections for the 1998-2022 period]. Actas Urol Esp. 2012;36(9):521-6. Spanish. doi: 10.1016/j.acuro.2011.09.003. [PubMed: 22196967].
  • 13. Falebita OA, Mancini S, Kiely E, Comber H. Rising incidence of renal cell carcinoma in Ireland. Int Urol Nephrol. 2009;41(1):7-12. doi: 10.1007/s11255-008-9413-0. [PubMed: 18566909].
  • 14. Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-10. doi: 10.1016/j.aju.2017.11.017. [PubMed: 29892483]. [PubMed Central: PMC5992262].
  • 15. Tolou Ghamari Z. Prevalence of lung cancer in Isfahan province, Iran. J Egypt Natl Canc Inst. 2018;30(2):57-9. doi: 10.1016/j.jnci.2018.03.001. [PubMed: 29691096].
  • 16. Tolou-Ghamari Z, Tadayon F, Mazdak H. Prevalence of liver cancer in Isfahan province, Iran. Indonesia J Cancer. 2018;12(2):56. doi: 10.33371/ijoc.v12i2.578.
  • 17. Tolou-Ghamari Z. Prevalence of breast cancer in Isfahan province, Iran. Women Health Bull. 2018;5(4). doi: 10.5812/whb.82678.
  • 18. Tolou-Ghamari Z. Thyroid cancer in Isfahan province, Iran; prevalence and demographic characteristics. Jundishapur J Chron Dis Care. 2019;8(1). doi: 10.5812/jjcdc.86864.
  • 19. Tolou-Ghamari Z. Prevalence of stomach cancer in Isfahan province, Iran. Gulf J Oncol. 2018;8(1). doi: 10.5812/whb.82678.
  • 20. Tolou-Ghamari Z. Prevalence of skin cancer in Isfahan province, Iran. Jentashapir J Health Res. 2018;9(2). doi: 10.5812/jjhr.82743.
  • 21. Wong MCS, Goggins WB, Yip BHK, Fung FDH, Leung C, Fang Y, et al. Incidence and mortality of kidney cancer: Temporal patterns and global trends in 39 countries. Sci Rep. 2017;7(1):15698. doi: 10.1038/s41598-017-15922-4. [PubMed: 29146923]. [PubMed Central: PMC5691143].
  • 22. Hassanipour S, Namvar G, Fathalipour M, Salehiniya H. The incidence of kidney cancer in Iran: A systematic review and meta-analysis. Biomedicine (Taipei). 2018;8(2):9. doi: 10.1051/bmdcn/2018080209. [PubMed: 29806587]. [PubMed Central: PMC5992926].
  • 23. Medina-Rico M, Ramos HL, Lobo M, Romo J, Prada JG. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J. 2018;12(3):E154-62. doi: 10.5489/cuaj.4464. [PubMed: 29283089]. [PubMed Central: PMC5869042].
  • 24. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47(2):155-69. [PubMed: 12900009].
  • 25. GLOBOCAN 2012. Cancer incidence, mortality and prevalence worldwide. Canada: Kidney; 2017.
  • 26. Mohammadian M, Pakzad R, Towhidi F, Makhsosi BR, Ahmadi A, Salehiniya H. Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012. Clujul Med. 2017;90(3):286-93. doi: 10.15386/cjmed-691. [PubMed: 28781525]. [PubMed Central: PMC5536208].
  • 27. Tolou-Ghamari Z, Palizban AA. Laboratory monitoring of cyclosporine pre-dose concentration (C0) after kidney transplantation in Isfahan. Iran J Med Sci. 2015;28(2):81-5.
  • 28. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the Isfahan Kashani Hospital. Int J Prev Med. 2013;4(Suppl 2):S274-8. [PubMed: 23776737]. [PubMed Central: PMC3678231].
  • 29. Shaygannejad V, Tolou-Ghamari Z. What is the real fate of vitamin D in multiple sclerosis? Int J Prev Med. 2013;4(Suppl 2):S159-64. [PubMed: 23776718]. [PubMed Central: PMC3678212].
  • 30. Tolou-Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-based pharmacotherapy of epilepsy. Arch Neurosci. 2014;2(2). doi: 10.5812/archneurosci.18468.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments